Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Leukemia

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/leu.2013.232PMID 23925046
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways

  2012cited by this paper
• Update on therapy of chronic lymphocytic leukemia.

  2011cited by this paper
• The impact of PTEN regulation by CK2 on PI3K-dependent signaling and leukemia cell survival.

  2011cited by this paper
• Findings from the phase I clinical trials of CX-4945, an orally available inhibitor of CK2.

  2011cited by this paper
• Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options

  2010cited by this paper
• Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia.

  2010cited by this paper
• CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.

  2010cited by this paper
• Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia.

  2010cited by this paper
• Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy

  2009cited by this paper
• The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease

  2007cited by this paper
• Mechanisms of apoptosis-induction by rottlerin: therapeutic implications for B-CLL

  2006cited by this paper
• Protein kinase CK2 phosphorylates and upregulates Akt/PKB

  2005cited by this paper
• A sustained activation of PI3K/NF-κB pathway is critical for the survival of chronic lymphocytic leukemia B cells

  2004cited by this paper
• 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis.

  1997cited by this paper
• p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression.

  1993cited by this paper
• p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression

  1993cited by this paper

• Structure-guided design and evaluation of oxazolone-based PIM-1 kinase inhibitors with promising anticancer activity.

  2026cites this paper
• Silmitasertib, an FDA-designated orphan CK2 inhibitor, ameliorates neuropathology and motor dysfunction in a Huntington's disease mouse model.

  2026cites this paper
• Silmitasertib, an FDA-designated orphan CK2 Inhibitor, ameliorates neuropathology and motor dysfunction in a Huntington’s disease mouse model

  2025cites this paper
• Casein Kinase 2α Ablation Confers Protection Against Metabolic Dysfunction‐Associated Steatotic Liver Disease: Role of FUN14 Domain Containing 1‐Dependent Regulation of Mitophagy and Ferroptosis

  2025cites this paper
• Protein kinase CK2α is overexpressed in classical hodgkin lymphoma, regulates key signaling pathways, PD-L1 and may represent a new target for therapy

  2024cites this paper
• Grasping cryptic binding sites to neutralize drug resistance in the field of anticancer.

  2023cites this paper
• Strategies of Targeting CK2 in Drug Discovery: Challenges, Opportunities, and Emerging Prospects.

  2023cites this paper
• Casein Kinase 2 Signaling in White Matter Stroke

  2022cites this paper
• The chromosome 21 kinase DYRK1A: emerging roles in cancer biology and potential as a therapeutic target

  2022cites this paper
• In silico investigations identified Butyl Xanalterate to competently target CK2α (CSNK2A1) for therapy of chronic lymphocytic leukemia

  2022cites this paper
• The Role of Protein Kinase CK2 in Development and Disease Progression: A Critical Review

  2022cites this paper
• Anti-Growth, Anti-Angiogenic, and Pro-Apoptotic Effects by CX-4945, an Inhibitor of Casein Kinase 2, on HuCCT-1 Human Cholangiocarcinoma Cells via Control of Caspase-9/3, DR-4, STAT-3/STAT-5, Mcl-1, eIF-2α, and HIF-1α

  2022cites this paper
• Cooperative Blockade of CK2 and ATM Kinases Drives Apoptosis in VHL-Deficient Renal Carcinoma Cells through ROS Overproduction

  2021cites this paper
• Elevating CDCA3 levels in non-small cell lung cancer enhances sensitivity to platinum-based chemotherapy

  2021cites this paper
• 4,5,7‐Trisubstituted indeno[1,2‐b]indole inhibits CK2 activity in tumor cells equivalent to CX‐4945 and shows strong anti‐migratory effects

  2021cites this paper
• Elevating CDCA3 levels in non-small cell lung cancer enhances sensitivity to platinum-based chemotherapy

  2021cites this paper
• Protein kinase CK2: a potential therapeutic target for diverse human diseases

  2021cites this paper
• Contribution of the CK2 Catalytic Isoforms α and α’ to the Glycolytic Phenotype of Tumor Cells

  2021influential citation
• Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo

  2020cites this paper
• Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy – potential clinical relevance

  2020cites this paper
• Inactivation of paracellular cation-selective claudin-2 channels attenuates immune-mediated experimental colitis in mice.

  2020cites this paper
• Clinical-Grade Peptide-Based Inhibition of CK2 Blocks Viability and Proliferation of T-ALL Cells and Counteracts IL-7 Stimulation and Stromal Support

  2020cites this paper
• Role of BRD4 phosphorylation in the nucleus accumbens in relapse to cocaine-seeking behavior in mice.

  2020cites this paper
• Role of protein kinase CK2 in antitumor drug resistance

  2019influential citation
• Protein Kinase CK2, a Potential Therapeutic Target in Carcinoma Management

  2019influential citation
• Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia

  2019influential citation
• CK 2 in Cancer : Cellular and Biochemical Mechanisms and Potential Therapeutic Target

  2019cites this paper
• Gene Expression and Regulation in Mammalian Cells - Transcription From General Aspects

  2018cites this paper
• Phosphorylation of PRH/HHEX by Protein Kinase CK2 Regulates Cell Proliferation and Cell Migration in Diverse Cell Types Phosphorylation of PRH/HHEX by Protein Kinase CK2 Regulates Cell Proliferation and Cell Migration in Diverse Cell Types

  2018cites this paper
• Design, synthesis, and evaluation of 4,5,6,7-tetrahydrobenzo[d]thiazole-based novel dual kinase inhibitors of CK2 and GSK3β.

  2018cites this paper
• CK2 regulates 5-HT4 receptor signaling and modulates depressive-like behavior

  2018cites this paper
• Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery

  2018cites this paper
• CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target

  2017cites this paper
• Structural Hypervariability of the Two Human Protein Kinase CK2 Catalytic Subunit Paralogs Revealed by Complex Structures with a Flavonol- and a Thieno[2,3-d]pyrimidine-Based Inhibitor †

  2017cites this paper
• Halogen and Hydrogen Bonding in Multicomponent Crystals of Tetrabromo-1H-Benzotriazole

  2017cites this paper
• Structural analysis of PIM1 kinase complexes with ATP-competitive inhibitors

  2017cites this paper
• Constitutive Phosphorylation of STAT3 by the CK2–BLNK–CD5 Complex

  2017cites this paper
• Casein Kinase II (CK2), Glycogen Synthase Kinase-3 (GSK-3) and Ikaros mediated regulation of leukemia.

  2017cites this paper
• Protein Kinase CK2: Intricate Relationships within Regulatory Cellular Networks

  2017cites this paper
• Generation and quantitative proteomics analysis of CK2α/α’(−/−) cells

  2017cites this paper
• CK2 and PI3K are direct molecular targets of quercetin in chronic lymphocytic leukaemia

  2017cites this paper
• Inhibition of casein kinase 2 prevents growth of human osteosarcoma.

  2017cites this paper
• Tuning response to therapy in preclinical GL261 glioblastoma through CK2 targeting and temozolomide metronomic approaches: non-invasive assessment with MRI and MRSI-based molecular imaging strategies

  2017cites this paper
• Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice

  2017cites this paper
• Therapeutic targeting of CK2 in acute and chronic leukemias

  2017cites this paper
• Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones

  2017cites this paper
• Targeting CK2-driven non-oncogene addiction in B-cell tumors

  2016cites this paper
• Increased occurrence of protein kinase CK2 in astrocytes in Alzheimer’s disease pathology

  2016cites this paper
• CK2 inhibition induced PDK4-AMPK axis regulates metabolic adaptation and survival responses in glioma.

  2016cites this paper
• Rapid Detection of Dynamic PTEN Regulation in Living Cells Using Intramolecular BRET.

  2016cites this paper
• CK2α' Drives Lung Cancer Metastasis by Targeting BRMS1 Nuclear Export and Degradation.

  2016cites this paper
• Casein kinases as potential therapeutic targets

  2016cites this paper
• TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity

  2016cites this paper
• Protein Kinase CK2 Regulates Leukocyte-Endothelial Cell Interactions during Ischemia and Reperfusion in Striated Skin Muscle

  2016cites this paper
• Pharmacological Targeting of the Inflamed Intestinal Barrier.

  2016cites this paper
• The role and regulation of AKT in CD40-mediated survival and proliferation of CLL cells

  2016cites this paper
• Drugging Undruggable Molecular Cancer Targets.

  2016cites this paper
• Kinases, tails and more: regulation of PTEN function by phosphorylation.

  2015cites this paper
• Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia.

  2015cites this paper
• B-Chronic Lymphocytic Leukemia Autophagyc Cell Death by the Use of Manganese Doped Zinc Oxide Nanoparticles and PhotoDynamic Therapy.

  2015cites this paper
• Zinc Oxide Nanoparticles and Photodynamic Therapy for the Treatment of B-chronic Lymphocytic Leukemia

  2015cites this paper
• Protein Kinase CK2: Systematic Relationships with Other Posttranslational Modifications

  2015cites this paper
• Study of PI3K/Akt signaling pathway as potential molecular target for T-cell acute lymphoblastic leukemia (T-ALL) treatment: pan-inhibition of PI3K catalitic isoforms as better therapeutic approach

  2015cites this paper
• Pharmaceutical composition for preventing and treating degenerative brain diseases, containing cx-4945 as active ingredient

  2015cites this paper
• A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours

  2015cites this paper
• Phosphoproteomics Identifies CK2 as a Negative Regulator of Beige Adipocyte Thermogenesis and Energy Expenditure.

  2015cites this paper
• The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies

  2015influential citation
• Inhibition of protein kinase CK2 suppresses tumor necrosis factor (TNF)-α-induced leukocyte-endothelial cell interaction.

  2015cites this paper
• Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia

  2014cites this paper
• The therapeutic potential of targeting the epithelial–mesenchymal transition in cancer

  2014cites this paper
• Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation

  2014cites this paper
• ER stress signaling in ARPE-19 cells after inhibition of protein kinase CK2 by CX-4945.

  2014cites this paper
• Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2

  2014cites this paper
• Casein kinase: the triple meaning of a misnomer.

  2014cites this paper
• Exploring the prominent performance of CX-4945 derivatives as protein kinase CK2 inhibitors by a combined computational study.

  2014cites this paper
• Zinc Signaling and Cancer

  2014cites this paper
• Zinc Signals in Cellular Functions and Disorders

  2014cites this paper
• Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling

  2014cites this paper
• Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specifc cell-permeable peptide inhibitor

  2013cites this paper
• Casein Kinase 2: a novel player in glioblastoma therapy and cancer stem cells.

  2013cites this paper